Private equity firm Advent International and Singapore wealth fund GIC have agreed to buy drugmaker Swedish Orphan Biovitrum AB for USD 8bn, in the largest buyout of a Nordic company in more than five years - provided a larger bid doesn't appear.
Investors will receive USD 27 (SEK 235) in cash for each share, the companies said Thursday. That’s 35 percent higher than the closing price as of Aug. 25, the day before Bloomberg reported that Advent was exploring the acquisition of the Swedish biotech firm, which is developing treatments for rare diseases.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for AMWatch has now started
With your free trial you get:
Full access to all locked articles on AMWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.
More from AMWatch
Sweden's largest fund manager is launching a climate impact fund with Swedbank's insurance unit as anchor investor. "We've had some great interest from larger investors and are in close contact with several potential investors that have expressed an interest," the new fund's portfolio manager tells AMWatch.